RxDoctor Payments Data

Yasamin Khanian-Najafabadi, DO

Internal Medicine · San Antonio, TXNPI 1245727239

Payments from drug & device makers

$409in general payments, 2019–2025

Across 20 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$86
  • Boehringer Ingelheim$63
  • Medtronic$45
  • AstraZeneca$43
  • Lilly USA, LLC$35
  • GSK$33
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$409 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$142,824
Medicare patients
415
Services billed
1,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$80,328
JardianceEmpagliflozin54$76,446
MounjaroTirzepatide71$75,392
EliquisApixaban30$35,520
JanuviaSitagliptin Phosphate13$18,027
FarxigaDapagliflozin Propanediol17$14,948
MyrbetriqMirabegron12$14,802
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,345
Levothyroxine Sodium382$4,672
Rosuvastatin Calcium314$3,707
PremarinEstrogens, Conjugated23$3,252
SynthroidLevothyroxine Sodium62$3,196
Atorvastatin Calcium294$2,620
Losartan Potassium222$2,447
Duloxetine Hcl86$2,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$26$80,32860 claims
Boehringer IngelheimJardiance$63$76,44654 claims
Lilly USA, LLCMounjaro$35$75,39271 claims
MerckJanuvia$86$18,02713 claims
AstraZenecaFarxiga$43$14,94817 claims
AbbVieSynthroid$14$3,19662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →